DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The goal is to investigate the pharmacokinetic properties of dry powder tobramycin via the
Cyclops® at different dosages in children with cystic fibrosis, together with the local
tolerability.